Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RXi Pharmaceuticals, a biotechnology company, has completed dosing in Phase 1 study of RXI-109, a self-delivering RNAi compound.
Subscribe to our email newsletter
RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids.
RXi president and CEO Dr. Geert Cauwenbergh said sd rxRNA, as a technology, can be used locally over a range of concentrations in a safe and well-tolerated manner.
"In the past, concerns have been raised over the tolerability of RNAi compounds in clinical trials for systemic organ diseases," Dr. Cauwenbergh added.
"These clinical data in skin and dermis confirm our earlier observations in animal studies that RXi’s self delivering (sd) technology can be used safely for disease indications where local delivery is appropriate.
The study enrolled 15 subjects, scheduled to undergo abdominoplasty shortly, and administered single intradermal injections in a dose dependent manner to five cohorts of three subjects each.
RXI-109 was well tolerated by intradermal injection in the subjects who received an RXI-109 injection in two separate areas on the abdomen and placebo injections in two other areas of the abdomen.